Scarica l'app Stockscreener
0.1006
0.40%
0.0004
Precedente Chiudi:
$0.1002
Aprire:
$0.1011
Volume 24 ore:
5.13M
Relative Volume:
0.41
Capitalizzazione di mercato:
$14.52M
Reddito:
-
Utile/perdita netta:
$-119.76M
Rapporto P/E:
-0.0745
EPS:
-1.35
Flusso di cassa netto:
$-55.17M
1 W Prestazione:
-2.04%
1M Prestazione:
-59.84%
6M Prestazione:
-74.53%
1 anno Prestazione:
-86.13%
Intervallo 1D:
$0.098
$0.1048
Intervallo di 1 settimana:
$0.0976
$0.114
Portata 52W:
$0.0911
$1.50
Applied Therapeutics Inc Stock (APLT) Company Profile
Nome
Applied Therapeutics Inc
Settore
Industria
Telefono
212-220-9226
Indirizzo
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Confronta APLT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.1006 | 14.46M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-02 | Downgrade | UBS | Buy → Neutral |
| 2024-11-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-31 | Iniziato | William Blair | Outperform |
| 2024-03-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-22 | Iniziato | Leerink Partners | Outperform |
| 2022-01-04 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-08-27 | Downgrade | Goldman | Neutral → Sell |
| 2021-06-25 | Ripresa | Goldman | Neutral |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-04-22 | Iniziato | Goldman | Buy |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2019-06-10 | Iniziato | Citigroup | Buy |
| 2019-06-10 | Iniziato | Cowen | Outperform |
| 2019-06-10 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Applied Therapeutics Inc Borsa (APLT) Ultime notizie
Why Applied Therapeutics Inc. stock attracts global investorsTrend Reversal & Low Drawdown Momentum Ideas - ulpravda.ru
Bond Watch: Will Applied Therapeutics Inc. stock continue dividend increasesDip Buying & Daily Technical Forecast Reports - ulpravda.ru
Can Applied Therapeutics Inc. stock beat analyst upgradesJuly 2025 Selloffs & AI Enhanced Trading Signals - ulpravda.ru
Will Applied Therapeutics Inc. stock continue dividend increasesWeekly Market Report & Free Technical Pattern Based Buy Signals - ulpravda.ru
Aug Analyst Calls: Will Applied Therapeutics Inc. stock see insider buyingJuly 2025 Fed Impact & Low Risk Entry Point Guides - ulpravda.ru
Will Applied Therapeutics Inc. stock see insider buyingQuarterly Trade Review & Free Risk Controlled Daily Trade Plans - ulpravda.ru
Why Applied Therapeutics Inc. (2UV) stock is upgraded to buyTrade Analysis Report & Weekly Watchlist of Top Performers - ulpravda.ru
Published on: 2026-01-07 21:50:31 - ulpravda.ru
RSI Check: Why Applied Therapeutics Inc stock attracts global investorsJuly 2025 Technicals & Growth-Oriented Investment Plans - moha.gov.vn
Applied Therapeutics (APLT) Upgraded to Buy: Here's Why - MSN
Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options - MSN
EBITDA per share of Applied Therapeutics, Inc. – FWB:2UV - TradingView — Track All Markets
Applied Therapeutics $15M Securities Class Action Settlement - Claim Depot
Applied Therapeutics (APLT) price target decreased by 85.00% to 0.26 - MSN
Why Applied Therapeutics Inc. stock remains a top recommendationMarket Sentiment Summary & Fast Moving Trade Plans - bolumsonucanavari.com
What analyst consensus says on Applied Therapeutics Inc. stockStop Loss & Risk Managed Investment Strategies - Улправда
Is Applied Therapeutics Inc. (2UV) stock cheap vs fundamentalsWeekly Stock Summary & Real-Time Market Sentiment Reports - Улправда
Will Applied Therapeutics Inc. stock maintain momentum in 2025 - Bölüm Sonu Canavarı
Is Applied Therapeutics Inc. stock a safe buy before earningsQuarterly Market Review & Fast Gaining Stock Strategy Reports - Улправда
How Applied Therapeutics Inc. (2UV) stock stacks up against competitorsMarket Performance Report & Safe Swing Trade Setup Alerts - DonanımHaber
Why Applied Therapeutics Inc. stock is recommended by analysts2025 Fundamental Recap & Long-Term Investment Growth Plans - Улправда
Applied Therapeutics, Inc.(NasdaqCM: APLT) dropped from NASDAQ Biotechnology Index - marketscreener.com
Published on: 2025-12-19 02:08:41 - Улправда
Dir Kanter Sells 43,000 ($4.8K) Of Applied Therapeutics Inc [APLT] - TradingView — Track All Markets
Applied Therapeutics (APLT) director reports sale of 43,000 shares on Form 4 - Stock Titan
Published on: 2025-12-18 17:03:31 - Улправда
Applied Therapeutics Earnings Notes - Trefis
United StatesGoodwin Represents Cycle Pharmaceuticals In Acquisition Of Applied Therapeutics - Mondaq
Here's Why Applied Therapeutics (APLT) Is a Great 'Buy the Bottom' Stock Now - Finviz
Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Dir Kanter Files To Sell 43,000 Of Applied Therapeutics Inc [APLT] - TradingView — Track All Markets
British drugs company Cycle Pharma snaps up US competitor - The Times
Applied Therapeutics announces merger with Cycle Group - MSN
Halper Sadeh LLC Encourages ALEX, DXLG, APLT Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Applied Therapeutics to be acquired by Cycle Pharmaceuticals - MSN
RBC Capital Sticks to Its Hold Rating for Applied Therapeutics (APLT) - The Globe and Mail
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger-ALEX, DVS, DXLG, and APLT - The Malaysian Reserve
Applied Therapeutics stock rating downgraded to Neutral by Baird - Investing.com Canada
Cycle buying Applied Therapeutics to develop CNS drugs - BioWorld MedTech
S&P 500 Down 1%; Broadcom Earnings Top Views - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Cycle Pharma to acquire Applied Therapeutics - The Pharma Letter
Cycle Group Holdings Limited entered into a definitive agreement to acquire Applied Therapeutics, Inc. for $13.4 million. - marketscreener.com
Dow Rises Over 100 Points; Lululemon Posts Upbeat Q3 Earnings - Benzinga
Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025) - ts2.tech
RBC Cuts Price Target on Applied Therapeutics to $0.25 From $1, Keeps Sector Perform, Speculative Risk - marketscreener.com
APLT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Applied Therapeutics, Inc. is Fair to Shareholders - The AI Journal
Applied Therapeutics Announces Merger with Cycle Group - TipRanks
Applied Therapeutics plunges after UK's Cycle Group to buy co - TradingView — Track All Markets
Applied Therapeutics stock price target lowered by RBC on Cycle acquisition - Investing.com Canada
Why Lululemon Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Applied Therapeutics Inc Azioni (APLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):